The authors describe an HIV-infected patient with moderate renal failure receiving combination antiretroviral therapy. Because of dyslipidaemia he was initially treated with pravastatin but developed rhabdomyolysis after a switch to rosuvastatin. With this case we illustrate that statins as well as antiretroviral therapy are susceptible to clinical relevant drug-drug or drug-disease interactions. Knowledge of these interactions is important to provide patients with the best possible care.
Since the introduction of combination antiretroviral therapy the lifetime expectancy of HIV-infected patients has increased tremendously. As patients are living longer with HIV, it is also important to pay attention to the prevention and treatment of comorbidities and their risk factors, such as dyslipidaemia.
Hydroxymethylglutaryl CoA reductase inhibitors (statins) can be used to treat dyslipidaemia in these patients. Knowledge of the pharmacokinetics of the different statins is necessary to avoid or anticipate possible interactions with simultaneously used antiretroviral therapy to prevent adverse effects [1, 2] . Here, we describe an HIV-infected patient with decreased renal function who developed rhabdomyolysis on rosuvastatin.
Case report
A 60-year-old Indonesian-Caucasian man (weight 60 kg) was admitted to our hospital because of hematuria and dyspnea on exertion and fatigue. Physical examination showed a pale, ash grey and ill man with abdominal pressure pain especially in the left kidney bed. His blood pressure was 130/80 mmHg, with a regular pulse rate of 100 beats per minute. His medical history included HIV infection, hyperlipidaemia, polyneuropathy and benign prostate hyperplasia. He had moderate renal failure with a serum creatinine of approximately 1.75 mg/dl (155 µmol/l, an estimated creatinine clearance of 38 ml/min). Five months before he was admitted to the hospital, he was told to reduce the dose of tenofovir 245 mg once daily to once every other day. At the same time, the patient switched from pravastatin 40 mg to rosuvastatin 40 mg because of vascular pathology. Additional chronic medications included the HIV protease inhibitor lopinavir/ritonavir 400/100 mg twice a day and the nucleoside reverse transcriptase inhibitor abacavir 300 mg twice a day. Furthermore, he took tamsulosin 0.4 mg daily, acetylsalicylic acid 80 mg daily, gemfibrozil 600 mg twice a day, amitriptyline 25 mg twice a day and gabapentin 400 mg three times a day. Until 1 month before admission he had also used tramadol 50 mg three times a day. He started with ciprofloxacin 500 mg twice a day for an urinary tract infection 5 days before admission. Laboratory evaluation at admission revealed a creatine kinase of 37,550 IU/l, aspartate aminotransferase of 828 IU/l, alanine aminotransferase of 298 IU/l, serum creatinine of 1.75 mg/l, urea of 8.9 mmol/l, sodium of 134 mEq/l, potassium of 2.9 mEq/l and phosphate of 2.52 mEq/l.
The clinical diagnosis was rhabdomyolysis. The antiretroviral drugs, ciprofloxacin and rosuvastatin were all discontinued because a side effect or interaction was suspected. The patient was treated with forced , Peter P Koopmans 2, 3 , David M Burger Introduction diuresis (intravenous normal saline with bicarbonate). The creatine kinase peaked at 37,730 IU/l on the day of admission; thereafter, it declined gradually. At discharge (19 days after hospitalization), creatine kinase level was normal (69 IU/l), aspartate aminotransferase was 86 IU/l, alanine aminotransferase was 130 IU/l and the serum creatinine was 1.19 mg/dl. Antiretroviral therapy was restarted 16 days after admission and consisted of atazanavir/ritonavir 300/100 mg daily, abacavir 300 mg twice a day and raltegravir 400 mg twice a day. Pravastatin 40 mg daily was restarted for his hypercholesterolaemia 5 months after hospital discharge. No new signs of rhabdomyolysis have occurred since then.
Discussion
In recent years, HIV infection has been considered as a chronic disease. It is well known that the chance of cardiovascular events is elevated in HIV-infected patients. This is partially due to the disease itself but is also due to side effects of antiretroviral drugs, in particular, hypercholesterolaemia by protease inhibitors and non-nucleoside reverse-transcriptase inhibitors [1] . According to the guidelines it is recommended to treat dyslipidaemia with statins or fibrates (gemfibrozil or fenofibrate) [3, 4] . Treatment with statins is usually effective and safe apart from two uncommon but potentially serious adverse effects: elevations of liver enzymes and skeletal muscle abnormalities, ranging from benign myalgias to life-threatening rhabdomyolysis [5] . Risk factors for rhabdomyolysis include certain patient characteristics such as renal or hepatic disease, existing myopathic conditions, hypothyroidism, viral infections and genetic factors. Also the risk of myopathy appears to vary among the different statins and can be related to the concentration of statins in blood [6] . Knowledge of the pharmacokinetic properties of statins is important to avoid drug-drug interactions or other situations that can lead to an increase in the plasma concentrations of statins with consequently a higher risk of myopathy.
Different factors contributed to the development of rhabdomyolysis in the patient described above. In this case, the patient was using gemfibrozil and a statin at the same time. Combination therapy of a statin and a fibrate, such as gemfibrozil, can have an additional lipid-lowering effect but is not without risks. Because gemfibrozil and its metabolite are inhibitors of the membrane transporter OATP1B1, which is involved in the hepatic uptake of hydrophilic statins, simultaneous use can thus increase the plasma concentration of the statin. Gemfibrozil monotherapy also shows myotoxicity, so the combination of a statin and gemfibrozil could lead to additive or even synergistic pharmacodynamic effects. Moreover, the fibrates are primarily renally excreted, thus renal impairment, as seen in this patient, may increase the likelihood of rhabdomyolysis with concurrent use of statins [6] .
Secondly, renal failure, renal impairment, elevated serum creatinine, hypophosphataemia and proximal tubulopathy (including Fanconi syndrome) have been reported with the use of tenofovir in clinical practice [7] . Combination of lopinavir/ritonavir with tenofovir is known to increase the area under the concentration time curve of tenofovir by 32% and the minimal concentration by 51%. This increased exposure of tenofovir could potentiate its adverse events, including renal disorders [7] . It is possible that the interaction between lopinavir/ritonavir and tenofovir may have contributed to the decline in renal function and therefore to the risk of rhabdomyolysis.
Pravastatin has been recommended as a safe choice for the treatment of dyslipidaemia in HIV-infected patients who are treated with protease inhibitors because pravastatin is not a substrate for CYP3A [3] . It is, however, the statin with the lowest potency, and in this patient the more potent drug rosuvastatin was given because the effect of pravastatin appeared to be insufficient. High plasma levels of rosuvastatin probably have contributed to the rhabdomyolysis in this patient. Rosuvastatin is a substrate of the membrane transporter OATP1B1. Drugs such as lopinavir/ritonavir, but also gemfibrozil, inhibit this transporter and can enhance the plasma concentrations of these statins [2] . Because the plasma concentrations of rosuvastatin are enhanced by the concurrent use of lopinavir/ritonavir, it is advisable to start with 5 mg rosuvastatin per day [2, 8, 9] .
Pravastatin on the other hand is glucuronidated by UDP-glucuronosyl-transferase. This enzyme is induced by lopinavir/ritonavir. This means that the plasma concentration of pravastatin might be lower when using this statin in combination with lopinavir/ritonavir and that a higher dose of pravastatin (up to 80 mg/ day) should be considered if the lipid lowering effect is insufficient [2] .
According to the summary of product characteristics of Crestor ® (rosuvastatin) the recommended dose for patients with moderate renal failure (creatinine clearance <60 ml/min) is 5 mg rosuvastatin daily [10] . The 40 mg dosage is even contraindicated in patients with a creatinine clearance lower than 60 ml/min [10] . This high dosage is also contraindicated in Asian patients, for whom a 5 mg start dose is recommended [10] . This is because higher plasma concentrations of rosuvastatin are found in this population.
All these factors together could have contributed to the development of rhabdomyolysis in this patient. The calculated Naranjo-score is 9, which means a definite adverse drug event [11] . Usually the onset of muscle toxicity, such as rhabdomyolysis, is within weeks to months after the initiation of statin therapy but may occur at any time during treatment. Just 2 months before hospital admission, the patient did not show any signs of muscle toxicity and his creatine kinase was normal (92 IU/l). Ciprofloxacin was started 5 days before admission and might therefore have been the final trigger to cause rhabdomyolysis in this patient. Myalgia has been reported following ciprofloxacin treatment [12, 13] , and can lead to a pharmacodynamic interaction with statins. In a case report describing a patient who developed rhabdomyolysis after addition of ciprofloxacin to chronic simvastatin therapy, the authors suggested this might be due to a pharmacokinetic interaction [14] . Ciprofloxacin and simvastatin are both substrates for the drug efflux transporters P-glycoprotein and multiple drug resistance associated protein [14] . A pharmacokinetic interaction between ciprofloxacin and rosuvastatin is less likely because ciprofloxacin, as far as we know, does not affect the metabolic enzymes or membrane transporters for which rosuvastatin is a substrate, such as OATP1B1 [6, 14] . However, it seems more likely that the patient did not have hematuria on which the diagnosis of an urinary tract infection was based, but had myoglobulinuria, which can also colour the urine red to brown. In that case ciprofloxacin may not have played a role as rhabdomyolysis was already present in this patient at the time ciprofloxacin was started.
Conclusions
In conclusion, a combination of many factors might have contributed to the development of rhabdomyolysis in this case. This illustrates that it can be challenging to use statins in an HIV-infected patient with co-morbidities and organ failure because statins as well as antiretroviral therapy are susceptible to drugdrug or drug-disease interactions. A multidisciplinary approach and a close collaboration between clinicians and pharmacists are required to provide these patients with the best possible pharmacological care.
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